

Law360 Life Sciences Editorial Advisory Board

Law360, New York (March 10, 2015, 3:53 PM ET) -- Law360 is pleased to announce the formation of its 2015 Life Sciences editorial advisory board.

The purpose of the editorial advisory board is to get feedback on Law360's coverage and to gain insight from experts in the field on how best to shape future coverage.

The members of the 2015 Life Sciences Law360 editorial advisory board are:

Lisa Davis, Quarles & Brady LLP

Lisa Davis, a partner in Quarles & Brady's life sciences practice, brings full-spectrum experience across the industry's supply chain. From product development to final sale, she advises drug and device manufacturers, wholesalers and pharmacies on marketing, network development and payment issues.

Amy K. Dow, Epstein Becker Green

Amy K. Dow is a member of the firm in Epstein Becker Green's health care and life sciences practice, in the firm's Chicago office. She primarily represents pharmaceutical, medical device and biologics manufacturers in U.S. Food and Drug Administration regulatory, fraud and abuse, and transactional matters. Dow also provides health regulatory due diligence services to private equity firms and other investors in life sciences sector entities.

Glenn Engelmann, McDermott Will & Emery LLP

Glenn Engelmann is senior counsel in the law firm of McDermott Will & Emery and is based in the firm's Washington, D.C., office. He serves as vice chair of the firm's life sciences industry group. Engelmann was selected as a Life Science Star by LMG Life Sciences, 2012-2014. He was also listed as a leading FDA lawyer in D.C. in The Best Lawyers in America 2015.

David Farber, King & Spalding LLP

David Farber is a partner in the King & Spalding FDA life sciences practice, where he maintains a legislative, regulatory and litigation practice focused on the life sciences industry. Farber's work focuses on life sciences issues before Congress, the FDA and the Centers for Medicare & Medicaid Services. He is an expert on coding and coverage issues across the federal health care programs.

Wendy Goldstein, Cooley LLP

Wendy C. Goldstein is a member of the Cooley business department and is a partner in the firm's health care and life sciences regulatory practice. She is resident in the New York office. Goldstein concentrates in health care fraud and abuse and government health care program matters relevant to manufacturers, payors and other ancillary providers in the health care life sciences space. She also represents those entities that invest in such concerns.

Christopher Jackson, Cohen & Gresser LLP

Christopher Jackson is counsel in Cohen & Gresser's New York office. His practice focuses on products liability and Medicaid fraud litigation, patent litigation, and complex commercial litigation. He has deep experience in the life sciences sector, including cases relating to product licensing, drug development, regulatory approvals and marketing.

Adem Koyuncu, Covington & Burling LLP

Adem Koyuncu is a lawyer and medical doctor and partner of Covington in Brussels. He is member of the firm's life sciences and compliance practice and advises clients on a range of regulatory and compliance issues in Europe. He has also worked in the pharmaceutical industry and as medical doctor.

Marian Lee, Gibson Dunn

Marian J. Lee is a partner at Gibson Dunn, where she provides FDA regulatory and compliance counseling to life science and health care companies. Lee has significant experience advising clients on FDA regulatory strategy, risk management and enforcement actions. Law360 recognized her as a Rising Star in her field, and she serves on the Food and Drug Law Institute's Policy Forum Advisory Board. Lee graduated from Harvard Law School and Harvard College, magna cum laude, and Phi Beta Kappa.

Steve Mahinka, Morgan Lewis & Bockius LLP

Stephen Paul Mahinka chairs Morgan Lewis' life sciences industry group, one of the nation's largest. He has practiced in both the FDA regulatory and antitrust areas throughout his career, and is the founder of the firm's FDA practice and a former leader of its antitrust practice.

Gavin Parsons, Troutman Sanders LLP

Gavin Parsons is a litigation partner in the Raleigh office of Troutman Sanders. He represents clients in a range of industries, including energy, manufacturing, communications, local government, hospitality and pharmaceuticals. He litigates claims involving business disputes, intellectual property, antitrust, catastrophic personal injury, wrongful death, mass tort, lawyer malpractice, land use and property rights, civil rights, insurance coverage and bad faith.

Robert N. Sahr, Choate Hall & Stewart LLP

Robert Sahr is a registered patent attorney and member of the life sciences team at Choate. He brings a sophisticated understanding of patent and regulatory law to his practice, advising clients seeking to establish exclusivity for their own commercial activities while navigating space that may potentially belong to others. Prior to practicing law, Sahr was a pharmaceutical research and development scientist at Eli Lilly & Co.

Robyn Shapiro, Drinker Biddle & Reath LLP

Robyn Shapiro, chair of Drinker Biddle's life sciences group, counsels emerging and established medical device, pharmaceutical and biotechnology companies, as well as academic medical centers, hospitals and contract research organizations, on complex regulatory issues relating to product development, with a focus on research compliance. She has served as an appointed member on a number of FDA and U.S. Department of Health and Human Services advisory committees.

Erik Snapp, Dechert LLP

Erik Snapp is a partner in Dechert's Chicago office. He defends pharmaceutical, medical device and consumer products clients in consumer fraud and product liability litigation. He has extensive trial

experience, has handled regulatory and internal investigations in the United States and Europe, and has advised clients on marketing/promotion issues.

James Stansel, Sidley Austin LLP

James Stansel is co-head of Sidley Austin's global life sciences team and is a former acting general counsel of the HHS. He represents health care manufacturers and providers on an array of regulatory and enforcement issues, including coverage, coding and reimbursement, off-label promotion and anti-kickback matters.

Michael Walsh, Strasburger & Price LLP

Michael Walsh is a partner in the Dallas office of Strasburger & Price and leads the firm's food and drug law industry team. Mike devotes his practice to counselling clients on regulatory compliance issues and defending complex litigation matters. Mike is a member of the Federation of Defense and Corporate Counsel and author of the "Supply and Distribution of FDA Regulated Products," published in December 2014.